Drug Trial Radar · NCT05624450
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,527
Planned (sponsor's estimate)
Start
Dec 13, 2022
Primary completion
Nov 4, 2027
Study completion Nov 4, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Conditions
- Viral Lung Infection and Acute Respiratory Failure
Interventions
TozorakimabDrug
Single IV dose of tozorakimab on Day 1.
PlaceboDrug
Single IV dose of matching placebo on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)Time frame: by Day 28
Locations
473 sites in 39 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Not yet recruiting
Research Site
Mobile, Alabama · Recruiting
Research Site
Phoenix, Arizona · Completed
Research Site
Phoenix, Arizona · Withdrawn
Research Site
Tucson, Arizona · Recruiting
Research Site
Chula Vista, California · Withdrawn
Research Site
Fresno, California · Recruiting
Research Site
La Mesa, California · Withdrawn
Research Site
Los Angeles, California · Withdrawn
Research Site
Newport Beach, California · Recruiting
Research Site
Torrance, California · Recruiting
Research Site
Colorado Springs, Colorado · Recruiting
Research Site
Denver, Colorado · Withdrawn
Research Site
Washington D.C., District of Columbia · Recruiting
Research Site
Bradenton, Florida · Completed
Research Site
Bradenton, Florida · Withdrawn
Research Site
Gainesville, Florida · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Lakeland, Florida · Recruiting
Research Site
Miami, Florida · Withdrawn
Research Site
South Pasadena, Florida · Completed
Research Site
St. Petersburg, Florida · Withdrawn
Research Site
Tampa, Florida · Recruiting
Research Site
Atlanta, Georgia · Withdrawn
Research Site
Boise, Idaho · Recruiting
Research Site
Chicago, Illinois · Completed
Research Site
Elmhurst, Illinois · Withdrawn
Research Site
Evanston, Illinois · Recruiting
Research Site
Fort Wayne, Indiana · Withdrawn
Research Site
Iowa City, Iowa · Withdrawn
Research Site
Kansas City, Kansas · Withdrawn
Research Site
Louisville, Kentucky · Recruiting
Research Site
Baton Rouge, Louisiana · Recruiting
Research Site
New Orleans, Louisiana · Withdrawn
Research Site
Shreveport, Louisiana · Completed
Research Site
Annapolis, Maryland · Recruiting
Research Site
Silver Spring, Maryland · Completed
Research Site
Springfield, Massachusetts · Completed
Research Site
Worcester, Massachusetts · Completed
Research Site
Detroit, Michigan · Recruiting
Showing 40 of 473 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.